BriaCell Therapeutics Announces Complete Resolution Of Lung Metastasis In Patient With Metastatic Breast Cancer Treated With Bria-OTS, Personalized Off The Shelf Immunotherapy

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces the durable and sustained complete resolution of a lung metastasis in a patient with metastatic breast cancer (MBC) treated with Bria-OTS, BriaCell's personalized off the shelf immunotherapy. The patient is hormone receptor-positive (HR+), HER2-negative.

The first patient enrolled in the Bria-OTS study, a 78-year-old woman with advanced metastatic breast cancer and multiple prior treatment failures, achieved complete (100%) resolution of a lung metastasis following four doses of Bria-OTS single agent therapy. The complete response, initially observed at 2 months (previously reported), was subsequently confirmed at 4 months (previously reported), 6 months (previously reported), and now at 11 months. The patient received 17 cycles of Bria-OTS, completed 12 months of the study, and remains in survival follow-up.